在治疗心血管假肢感染中使用长效脂糖类抗生素进行长期治疗:系统性审查
Francesca Gavaruzzi1, Guido Granata1, Alessandro Capone1
1Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.
Antibiotics (Basel, Switzerland)
|November 27, 2025
概括
像达尔巴万辛和奥里塔万辛这样的长期起作用的脂糖对治疗具有挑战性的格兰阳性心血管假肢感染有希望. 虽然作为巩固疗法有效,但它们用于慢性抑制的使用产生了不同的结果.
科学领域:
- 传染性疾病 传染性疾病
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 达尔巴万辛和奥里塔万辛是长期起作用的脂糖,用于治疗阳性感染.
- 仅有有限的证据证明它们在复杂的心血管假肢感染 (PVE,CIED,LVAD,PVGI) 中使用,由于生物膜和需要长期治疗,这些感染具有挑战性.
研究的目的:
- 系统地审查有关达尔巴万辛和奥里塔万辛治疗心血管假肢感染的文献.
- 总结治疗策略,临床结果和安全性概况.
主要方法:
- 在PubMed,Embase,Scopus和Cochrane图书馆进行系统的文献搜索,截至2025年6月24日.
- 包括对接受达尔巴万辛或奥里塔万辛治疗心血管假肢感染的成年人的研究.
- 提取有关患者人口统计,病原体,治疗方案,结果和不良事件的数据.
主要成果:
- 包括来自20项研究的113名患者;111人接受了dalbavancin.
- 达尔巴万辛在手术后/移除设备后的整合治疗中显示出高治愈率.
- 慢性抑制疗法具有复发的可变结果;不良事件是罕见和轻微的.
结论:
- 长效脂糖可能对心血管假肢感染有价值,特别是在源控制后作为巩固疗法.
- 慢性抑制疗法表现出异质的结果.
- 目前的文献主要以案例报告为主,表明需要进行更广泛的研究.
相关概念视频
Endocarditis III: Medical Management
200
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
200
Endocarditis IV: Nursing Management
305
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
305
Acute Pyelonephritis II: Diagnostic Studies and Management
291
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
291
Peripheral Artery Disease III: Interprofessional Care
229
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
229
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301


